Celgene Corp. (CELG) reported better-than-expected profit and revenue numbers for the third quarter of 2018 on strong product sales. Revenue climbed 18% to $3.89 billion and EPS jumped 20% to $2.29,  while analysts predictions for revenue and EPS stood at $3.83 billion and $2.23, respectively. The pharma company’s stock rose about 3% before the bell. … Continue reading Celgene plunges to new 52-week low despite beating Q3 estimates